Current progress in the development of human immunodeficiency virus vaccines: Research and clinical trials

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2210-2215

  Klein, Michel ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ALLOIMMUNIZATION; CONFERENCE PAPER; CONTROLLED STUDY; DEVELOPING COUNTRY; DISEASE CONTROL; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; MUCOSAL IMMUNITY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

AIDS VACCINES; ANIMALS; CLINICAL PROTOCOLS; CLINICAL TRIALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOASSAY; MODELS, ANIMAL; RESEARCH; T-LYMPHOCYTES;

EID: 0035925612     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00547-8     Document Type: Conference Paper

References (44)

1. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?
2. AIDS vaccine development in primate models
3. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
4. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
5. Human trials of HIV-1 vaccines
6. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
7. A human immunodeficiency prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dual tropic clade B and C primary isolates
8. Protective immunity induced by live attenuated simian immunodeficiency virus
9. Live attenuated AIDS virus: Promise or peril?
10. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
11. Human neutralizing monoclonal antibodies of the Ig1 subtype protect against mucosal simian-human immunodeficiency virus infection
12. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
13. Advancing AIDSVAX to Phase 3. Safety, immunogenicity and plans for Phase 3
14. AIDSVAX (MN) in Bangkok injecting drug users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization
15. Induction of HIV type 1 neutralizing and env-CD4-blocking antibodies by immunization with genetically engineered HIV type1-like particles containing unprocessed gp160 glycoproteins
16. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
17. A role for carbohydrates in immune evasion in AIDS
18. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding
19. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
20. Core structure of gp41 from the HIV envelope glycoprotein
21. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
22. Epitope-based vaccine induces high levels of ELDKWA epitope-specific neutralizing antibodies
23. Control of SHIV-89.K6P infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
24. Vaccination with Rev and Tat against AIDS
25. DNA vaccines
26. Alphavirus-based expression vectors: Strategies and applications
27. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency type 1 envelope protein and challenged with a high dose of SHIV-4 virus
28. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
29. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing Gag, Pol, Env, and Nef proteins
30. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
31. Neutralizing antibody independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations
32. Alloimmunization as a strategy for vaccine design against HIV/AIDS
33. Intranasal immunization of a DNA vaccine with IL-12 and granulocyte-macrophage stimulating factor (GM-CSF)-expressing plasmid in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
34. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization
35. Oral somatic transgene vaccination using attenuated S. typhimurium
36. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
37. Oral DNA vaccination promotes mucosal and systemic immune reponses to HIV envelope glycoprotein
38. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses
39. Immune control of HIV-1 after early treatment of acute infection
40. Boosting immunity to HIV - Can the virus help?
41. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine
42. HIV vaccine development and evaluation: Realistic expectations